Immune imprinting and SARS-CoV-2 vaccine design

Adam K Wheatley; Annette Fox; Hyon-Xhi Tan; Jennifer A Juno; Miles P Davenport; Kanta Subbarao; Stephen J Kent

doi:10.1016/j.it.2021.09.001

Immune imprinting and SARS-CoV-2 vaccine design

Trends Immunol. 2021 Nov;42(11):956-959. doi: 10.1016/j.it.2021.09.001. Epub 2021 Sep 15.

Authors

Adam K Wheatley¹, Annette Fox², Hyon-Xhi Tan¹, Jennifer A Juno¹, Miles P Davenport³, Kanta Subbarao⁴, Stephen J Kent⁵

Affiliations

¹ Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Australia.
² WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute, Melbourne, Australia.
³ Kirby Institute, University of NSW, Sydney, Australia.
⁴ Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Australia; WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute, Melbourne, Australia.
⁵ Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Australia. Electronic address: skent@unimelb.edu.au.

Abstract

Reformulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines with variant strains is being pursued to combat the global surge in infections. We hypothesize that this may be suboptimal due to immune imprinting from earlier vaccination or infection with the original SARS-CoV-2 strain. New strategies may be needed to improve efficacy of SARS-CoV-2 variant vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
SARS-CoV-2
Vaccines*

Substances

COVID-19 Vaccines
Vaccines